Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO · Mar 27, 2019

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how advanced liver cancer, known as hepatocellular carcinoma (HCC), affects older adults, particularly those who cannot have surgery to remove the tumor. The study aims to gather information from 84 participants aged 65 and older who have been newly diagnosed with this type of cancer. Researchers will use special assessments to evaluate the health and well-being of these participants and track any side effects they experience during the study. They are interested in how aging factors might influence both the disease and its treatment.

To be eligible for the trial, participants must be at least 18 years old and have a confirmed diagnosis of advanced, unresectable HCC. However, those who can still undergo surgery or have received previous treatments for their cancer will not be included. Participants can expect to undergo health evaluations and monitoring throughout the study, helping researchers learn more about treating liver cancer in older adults while ensuring their safety and care. This is an important step toward improving treatment options for this population.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically or radiographically (CT or MRI) confirmed newly diagnosed hepatocellular carcinoma.
• • Age 18 years and older.
• • Patients with advanced, unresectable HCC as determined by the treating physician.
• Exclusion Criteria:
• • Patients with resectable HCC who are still candidates for locoregional therapy
• • Patients receiving prior systemic or locoregional therapy